NCCR AntiResist

2020 series

Home institution: University of Basel

The NCCR “AntiResist” aims at developing new approaches to better understand the biochemical and biophysical processes caused by bacterial pathogens in infected patients, and to simulate them in tissue modelling. The findings will help researchers to develop new antibiotics more rapidly, and to identify new and innovative antimicrobial effect mechanisms on the basis of which new medicines can be developed.

Antibiotics play a vital role in many areas of modern medicine, especially protecting patients whose immune system has been weakened. But these achievements of modern medicine are now under threat. More and more strains of bacteria are becoming resistant to one or several types of antibiotics.

Therefore, the research will focus on four pathogens that cause major problems throughout the world. The NCCR’s overriding objective is to initiate a paradigm change in infection research by adopting an interdisciplinary approach that brings together research groups from the fields of clinical research, biology, chemistry, engineering and pharmacology.

  • Contact details

    Dropdown Icon

    NCCR Directorate

  • Funding

    Dropdown Icon

    Financing 2020 – 2023 (Swiss Francs):

    Funding source2020 – 2023
    SNSF grant17'000’000
    Total funding available28'000’000

    NCCRs are financed through grants awarded by the SNSF, but also from other sources. The home institution involved in the NCCR also contributes a substantial amount of money. The available overall budget of the NCCR is further increased by monetary contributions from the project participants and third-party funds, which are generally invested by industrial companies.